^
    Back
    Association details:
    Biomarker:EGFR G719C
    Cancer:Non Small Cell Lung Cancer
    Drug:erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib

    Excerpt:
    ...Exon 19 deletion; G719S, G719A, G719C mutations (Exon 19);or L861Q (laboratory report required at enrollment)....
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Sci
    Title:

    Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

    Excerpt:
    ...recent studies revealed that these rare genotypes could be targetable if appropriate TKI are selected. For example, G719X (X denotes A, S, C and so on), Del18, E709K, insertions in exon 19 (Ins19), S768I or L861Q showed moderate sensitivities to gefitinib or erlotinb with ORR of 30%–50%
    DOI:
    10.1111/cas.12996